Cellares is the first Integrated Development and Manufacturing Organization (IDMO) that takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is developing and operating integrated technologies for cell therapy manufacturing to meet the total patient demand for cell therapies globally.

Omar Kurdi

Fabian Gerlinghaus

Cellares

Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is both developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company’s Cell Shuttle integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation. Cell Shuttles will be deployed in Cellares’ Smart Factories around the world to meet total patient demand for cell therapies at global scale. Partnering with Cellares enables academics, biotechs, and pharma companies to accelerate drug development and scale out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand.

The company is headquartered in South San Francisco, California with its commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. The company is backed by world-class investors and has raised over $355 million in financing.

Eclipse Ventures

EcoR1 Capital

Skyviews Life Science

Decheng Capital

Willett Advisors LLC

Koch Disruptive Technologies

Bristol-Myers Squibb

DFJ Growth

Rodney L Rietze, PhD, Co-Founder and CEO of iVexSol, and Cellares Advisory Board Member, discusses how an Integrated Development Manufacturing Organization's (IDMO) transformative technology seamlessly integrate unit operations and break the bottlenecks of cell therapy manufacturing scalability.

Watch the full video here: https://lnkd.in/gNYwsE3U

ℹ️ Cellares TAP Program is ending soon ℹ️

#IDMO #celltherapymanufacturing
https://lnkd.in/e7Xb8ANt

Watch Timothy Moore, CTO at Allogene Therapeutics and Cellares Advisory Board Member, discuss the constraints of conventional CDMOs and how an Integrated Development and Manufacturing Organization (IDMO) can help the industry scale manufacturing to meet the global patient demand for cell therapies.

Click here to see the full interview:

https://lnkd.in/gzbVQPw7

Cellares’ Series C Fundraising Triumph: Launching A New Smart Factory In Somerset County, NJ

Learn more & get our take 👇
https://lnkd.in/gHcrUnm3

“We’re excited to welcome Cellares to the life sciences hub of New Jersey,” – Shanel Robinson, Commissioner Director at Somerset County

“The opening of this facility marks a tremendous milestone towards Cellares’ mission of accelerating access to life-saving cell therapies to meet total global patient demand,” – John Tomtishen, Sr. Vice President and General Manager at Bridgewater IDMO Smart Factory

“Not only does Cellares join a thriving Life Sciences industry here, but they reinforce the fact that many of the cures needed by the world come from Somerset County,” – Jessica Paolini, Manager of Economic Development at Somerset County

#funding #lifesciences #SoHCNews

Metric
Company Name	Cellares
Symbol
MSH ID	COM:CELLARES
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage	Series C
Employee Count	174
Website	cellares.com
LinkedIn	cellares-corporation
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	7.68K
Web Traffic Growth	-0.60
Valuation
Raised Capital	255M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:CELLARES

Cellares

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue